0001628280-26-054525
SEC filingNatera Q2营收$752.8M同比+37.7%,量价齐升与Signatera结构改善推动毛利率提升,但R&D激增致经营亏损$75.8M。
| 指标 | 本期(Q2 2026) | 去年同期(Q2 2025) | 同比 |
|---|---|---|---|
| Total Revenues | $752.8M | $546.6M | +37.7% |
| Product Revenues | $747.9M | $544.4M | +37.4% |
| Licensing and Other Revenues | $4.8M | $2.2M | +121.9% |
| Cost of Product Revenues | $266.6M | $199.5M | +33.6% |
| Loss from Operations | -$75.8M | -$110.4M | 亏损收窄31.3% |
| Net Loss | -$67.0M | -$100.9M | 亏损收窄33.7% |
Q2总营收$752.8M,同比+37.7%(+$206.2M),增长桥由量价双轮驱动:报告单位约985,500,同比+21.2%(+172,600单位);ASP同比+13.3%,主因Signatera占比提升(其ASP高于women's health产品)及第三方支付方覆盖改善。产品收入$747.9M(+37.4%),licensing and other revenues $4.8M(+121.9%),后者主要来自合作开发协议收入增长。
成本端,cost of product revenues $266.6M同比+33.6%,增速低于收入,占产品收入比重由36.6%降至35.6%(改善约100bps),归因于高销量产品单位成本更低的产品结构变化,以及历史检测回款估计变更带来的收入增额。费用端分化明显:R&D $228.1M同比+55.8%(+$81.6M),主因人员薪酬+$28.3M、实验室及临床试验+$37.0M;SG&A仅+5.4%至$327.2M,其中法律及咨询费用减少$38.6M形成对冲。经营亏损收窄至$75.8M(上年-$110.4M),净亏损$67.0M(上年-$100.9M)。
盈利质量需关注估计变更:Q2因历史期间检测超额回款确认收入估计变更增额$52.3M,较上年同期多$7.0M;上半年累计$113.3M(上年同期$79.6M),该非现金性质的回款改善直接增厚经营现金流,但属持续性待观察项。另Foresight Diagnostics并购带来无形资产摊销$5.7M(上年为零),为非现金费用。
| 分部 | 营收 | 同比 | 经营利润/EBITDA | 利润率 | 驱动 |
|---|---|---|---|---|---|
| Product revenues | $747.9M | +37.4% | — | — | Signatera占比提升带动ASP+13.3%,报告单位+21.2% |
| Licensing and other revenues | $4.8M | +121.9% | — | — | 合作开发协议收入增加 |
注:公司未按 oncology / women's health / organ health 披露分部收入或分部利润,上表按收入类型列示;分部级利润率未披露。
| 项目 | 本期末 | 上期末 | 变化 |
|---|---|---|---|
| Cash, cash equivalents and restricted cash | $1,091.5M | $1,076.1M | +$15.4M |
| Marketable securities | $0 | $0 | — |
| Total Debt(Short-term debt financing,含应计利息) | $80.3M | $80.3M | 基本持平 |
| Net Debt | $1,010.8M(净现金) | $995.8M(净现金) | — |
| Inventory | $80.3M | $68.4M | +$11.9M |
| Deferred revenue(流动$40.6M+非流动$16.1M) | $56.6M | $42.0M | +$14.7M |
| Shareholders' Equity | $1,821.5M | $1,712.4M | +$109.1M |
| 项目 | 金额/内容 | 说明 |
|---|---|---|
| Buybacks | 未披露 | Notes 未披露回购计划或授权余额 |
| Dividends | 未披露 | 未派息 |
| 债务变化(净) | 基本持平 | Credit Line 余额 $80.3M,公允价值≈账面值(30-day SOFR + 0.5%) |
| Capex(六个月,净) | $85.6M | 另有无现金应计设备采购 $15.3M;占六个月收入 5.9% |
| 股票薪酬(六个月) | $196.2M | 另以股票发放奖金 $47.0M |
| 股权发行(六个月) | 期权行权 $4.7M+ESPP $16.4M | 期末股本 143,612 千股 |
| 或有对价(Foresight) | $120.5M | 流动 $22.8M+非流动 $97.7M;里程碑上限 $175.0M |
| 法律或有事项计提 | $33.2M | Ravgen 案一审判决赔偿 $57.0M,已提起上诉 |
| 维度 | 三个月 2026 | 三个月 2025 | 六个月 2026 | 六个月 2025 |
|---|---|---|---|---|
| Insurance carriers | $705.1M | $517.0M | $1,363.2M | $989.6M |
| Laboratory partners | $37.7M | $22.2M | $66.6M | $43.0M |
| Patients | $9.9M | $7.4M | $19.7M | $15.8M |
| United States | $739.5M | $537.8M | $1,425.1M | $1,030.1M |
| Americas, excluding U.S. | $2.2M | $1.6M | $4.6M | $3.3M |
| Europe, Middle East, India, Africa | $9.0M | $5.4M | $15.4M | $11.5M |
| Asia Pacific and Other | $2.0M | $1.8M | $4.3M | $3.6M |
| 项目 | 本期 | 去年同期 |
|---|---|---|
| Operating Cash Flow | $94,964K | $82,026K |
| Capex (Purchases of property and equipment, net) | $85,566K | $47,712K |
| Free Cash Flow | — | — |
| FCF 转化率 (FCF/Net Income) | — | — |
| Share Repurchases | — | — |
| Dividends Paid | — | — |
上半年 CFO 为 9,496 万美元,同比增长 15.8%,但净亏损仍达 1.521 亿美元,现金流转正主要依赖 1.982 亿美元 Stock-based compensation 等非现金项目以及营运资本流入(Accrued compensation +5,890 万、Other accrued liabilities +4,312 万、Accounts payable +3,562 万),而 Accounts receivable 大幅流出 1.254 亿美元,显示回款节奏对现金流形成拖累。Capex 同比大增 79% 至 8,557 万美元,资本开支强度显著上升,几乎吞噬全部经营现金流;公司未披露 FCF、股份回购与分红,本期无资本返还,现金余额由 10.76 亿美元增至 10.92 亿美元。